Treatment with certain ACE inhibitors can prevent the breakdown of bradykinin and promote the formation of vasodilatory prostaglandins, which may explain higher levels of PGE2 in DCM hearts (42). The gene discussed is ACE; the disease is familial dilated cardiomyopathy.